Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice.

To determine the contribution of the mdr1a gene product to digoxin pharmacokinetics, we constructed a physiologically based pharmacokinetic model for digoxin in mdr1a (-/-) and mdr1a (+/+) mice. After intravenous administration, total body clearance and tissue-to-plasma concentration ratios for muscle and heart were decreased in mdr1a (-/-) mice as compared with mdr1a (+/+) mice, and in particular, the digoxin concentration in the brain was 68-fold higher than that in mdr1a (+/+) mice at 12 h. On the other hand, mdr1a gene disruption did not change the contributions of renal and bile clearances to total clearance, the plasma protein binding, or the blood-to-plasma partition coefficient. Brain concentration-time profiles in mdr1a (+/+) and mdr1a (-/-) mice showed a different pattern from those in plasma and other tissues, indicating digoxin accumulation in the brain tissue. Because there was no difference in the uptake or release of digoxin by brain tissue slices from the two types of mice, we assumed the brain tissue compartment to consist of two parts (a well-stirred part with influx and efflux clearance and an accumulative part). Simulation with this model gave excellent agreement with observation when active efflux clearance across the blood-brain barrier was assumed to be zero in mdr1a (-/-) mice. The observations in other tissues in both types of mice were also well simulated.

[1]  K. Speeg,et al.  Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. , 1992, The Journal of pharmacology and experimental therapeutics.

[2]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Tsuruo,et al.  P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. , 1992, Life sciences.

[4]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[5]  I. Tamai,et al.  In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. , 1994, Biochemical pharmacology.

[6]  Akira Tsuji,et al.  Drug delivery through the blood-brain barrier , 1996 .

[7]  Z. Gatmaitan,et al.  The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. , 1989, The Journal of biological chemistry.

[8]  Y. Tanigawara,et al.  Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. , 1993, The Journal of pharmacology and experimental therapeutics.

[9]  Z. Gatmaitan,et al.  The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. , 1992, Gastroenterology.

[10]  G. M. Pollack,et al.  Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. , 1998, The Journal of pharmacology and experimental therapeutics.

[11]  M. Gibaldi,et al.  Physiologically based pharmacokinetic model for digoxin distribution and elimination in the rat. , 1977, Journal of pharmaceutical sciences.

[12]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[13]  T. Terasaki,et al.  Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. , 1993, Biochemical pharmacology.

[14]  V. Stella,et al.  Prodrugs of phosphates, phosphonates, and phosphinates , 1996 .

[15]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Borst,et al.  Multidrug resistance and the role of P-glycoprotein knockout mice. , 1995, European journal of cancer.

[17]  T. Tsuruo,et al.  [Functional involvement of P-glycoprotein in blood-brain barrier]. , 1992, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[18]  T. Yamashima,et al.  In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. , 1995, Biochemical pharmacology.

[19]  T. Tsuruo,et al.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.

[20]  D. Housman,et al.  The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues , 1989, Molecular and cellular biology.

[21]  Piet Borst,et al.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein , 1996, British journal of pharmacology.

[22]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[23]  Y. Tanigawara,et al.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.

[24]  I. Tamai,et al.  Blood-brain barrier function of P-glycoprotein , 1997 .

[25]  Y. Sai,et al.  Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P‐Glycoprotein Functioning as an Absorption Barrier , 1996, The Journal of pharmacy and pharmacology.

[26]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[27]  F. Baas,et al.  Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. , 1993, Pharmacology & therapeutics.